SEC Comment Letter for Cellectar Biosciences, Inc. (CLRB) (CIK 0001279704) (CLRB) — May 31, 2016
Cellectar Biosciences, Inc. (CLRB) (CIK 0001279704)
Date: May 31, 2016 · CIK: 0001279704 · Accession: 0000000000-16-078537
AI Filing Summary & Sentiment
Reasoning
Letter
Mail Stop 4720 May 31, 2016 Chad J. Kolean Vice President, Chief Financial Officer and Treasurer Cellectar Biosciences, Inc. 3301 Agriculture Drive Madison, Wisconsin 53716
Re: Cellectar Biosciences, Inc. Preliminary Proxy Statement on Schedule 14A Filed May 13, 2016 File No. 001 -36598
Dear Mr. Kolean :
We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We u rge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.
Sincerely,
/s/ Erin K. Jaskot, for
Show Raw Text
Mail Stop 4720 May 31, 2016 Chad J. Kolean Vice President, Chief Financial Officer and Treasurer Cellectar Biosciences, Inc. 3301 Agriculture Drive Madison, Wisconsin 53716 Re: Cellectar Biosciences, Inc. Preliminary Proxy Statement on Schedule 14A Filed May 13, 2016 File No. 001 -36598 Dear Mr. Kolean : We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We u rge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Erin K. Jaskot, for Suzanne Hayes Assistant Director Office of Healthcare and Insurance